Pituitary tumor-transforming gene 1 as a proliferation marker lacking prognostic value in cutaneous squamous cell carcinoma
Pituitary tumor-transforming gene 1 as a proliferation marker lacking prognostic value in cutaneous squamous cell carcinoma
复制标题
DOI：
10.1111/exd.12118
复制
发表时间：
2013-05-01
影响因子：
3.6
通讯作者：
Otsuka, Fujio
中科院分区：
文献类型：
--
作者：
Ishitsuka, Yosuke;Kawachi, Yasuhiro;Otsuka, Fujio
非黑色素瘤皮肤癌是世界范围内最常见的癌症类型，由涉及原癌基因和肿瘤抑制基因表达失调的表皮癌发生和恶性进展引起。原癌基因垂体肿瘤转化基因1（PTTG 1）是一种广泛表达的转录因子，可促进培养的表皮角质形成细胞的增殖。为了研究PTTG 1在表皮癌发生和恶性进展中的潜在作用，通过免疫组织化学沿着Ki 67、角蛋白10（K10）和p53在皮肤鳞状细胞癌（SCC）、光化性角化病（AK）和Bowen病（BD）的组织样品中的表达进行分析。在这些疾病组中比较PTTG 1的表达水平，以测试与每个疾病组中的增殖、分化能力或突变的肿瘤抑制基因的存在的相关性。在每个疾病组中，PTTG 1的表达水平与Ki67的表达水平呈正相关，尽管通过K10表达测量的分化状态没有显示出任何相关性。相反，突变的p53蛋白的存在仅在SCC组中显示出正相关性。此外，PTTG 1在SCC中的表达水平与已知的预后因素如TNM分期或肿瘤厚度无关。这些结果表明，PTTG1可能代表与突变的p53蛋白相关的增殖标记物，但不是SCC不良临床结局的信息预测因子。
Non-melanoma skin cancer is the most frequently occurring type of cancer worldwide and is caused by epidermal carcinogenesis and malignant progression that involve dysregulated expression of proto-oncogenes and tumor suppressor genes. The proto-oncogene pituitary tumor-transforming gene 1 (PTTG1) is a ubiquitously expressed transcription factor that can promote enhanced proliferation of cultured epidermal keratinocytes. To investigate the potential roles of PTTG1 in epidermal carcinogenesis and malignant progression, the expression of PTTG1 was analysed by immunohistochemistry along with Ki67, keratin 10 (K10) and p53 in tissue samples of cutaneous squamous cell carcinomas (SCC), actinic keratoses (AK) and Bowen's disease (BD). Expression levels of PTTG1 were compared among these disease groups to test for correlations with proliferation, differentiation capacity or the existence of mutated tumor suppressor genes in each disease group. In each disease group, the expression levels of PTTG1 correlated positively with those of Ki67, although the differentiation status, measured by K10 expression, did not show any correlation. In contrast, the existence of mutated p53 proteins showed a positive correlation only in the SCC group. Moreover, the expression levels of PTTG1 in SCC did not correlate with known prognostic factors such as TNM staging or tumor thickness. These results suggest that PTTG1 may represent a proliferation marker associated with mutated p53 proteins but is not an informative predictor of poor clinical outcomes in SCC.